У нас вы можете посмотреть бесплатно Safety and tolerability of AMG 330, a bispecific T-cell engager, in adult patients with R/R AML или скачать в максимальном доступном качестве, которое было загружено на ютуб. Для скачивания выберите вариант из формы ниже:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса savevideohd.ru
Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, presents the safety and tolerability of AMG 330 in adults with relapsed/refractory (R/R) acute myeloid leukemia (AML). In a Phase I dose escalation trial (NCT02520427), AMG 330 elicited responses but was associated with toxicities such as cytokine release syndrome (CRS) and infusion reactions. Dr Ravandi is unsure whether this agent will move into further development, as focusing efforts on developing bispecific antibodies with AML-specific targets may confer greater therapeutic benefit. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.